• Explore /
  • Poster
  • / HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhyaluronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advanced or metastatic cholangiocarcinoma and gallbladder cancer.

HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhyaluronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advanced or metastatic cholangiocarcinoma and gallbladder cancer.

Abstract Poster

Authors

null

Mitesh J. Borad

Mayo Clinic, Scottsdale, AZ

Mitesh J. Borad , Rachna T. Shroff , Ghassan K. Abou-Alfa , J. Randolph Hecht , Andrea J. Bullock , Paul S. Ritch , Dimitrios Chondros , Mann Muhsin , Do-Youn Oh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT03267940

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr TPS543)

DOI

10.1200/JCO.2018.36.4_suppl.TPS543

Abstract #

TPS543

Poster Bd #

Q19

Abstract Disclosures

Similar Posters

First Author: Do-Youn Oh

First Author: Gang Jin

First Author: Ghassan K. Abou-Alfa

First Author: Chandrani Khatri